Selective serotonin reuptake inhibitors:: use in children and adolescents with major depressive disorder

被引:0
|
作者
Jimenez-Arriero, M. A.
Fernandez, I.
Vidal, J.
Herraez, C.
Parellada, M.
Cruz, M. A.
Perez-Cayuela, P.
Ausejo, M.
机构
[1] Hosp Univ Doce Octubre, Serv Madrileno Salud, Madrid, Spain
[2] Consejeria Sanidad & Consumo Comunidad Madrid, Dirrecc Gen Farm & Prod Sanitarios, Subdirecc Gen Asistencia Farmaceut, Madrid, Spain
来源
ACTAS ESPANOLAS DE PSIQUIATRIA | 2007年 / 35卷 / 05期
关键词
antidepressants; selective serotonin reputake inhibitors (SSRI); children; adolescents; major depressive suicide;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Treatment of depression in children and adolescents is a health care question of primary importance and it is presently associated to significant social concern. In recent years some studies have appeared that throw light on the question of the use of antidepressants in these sectors of the population in which they have been used. Information provided by national agencies, associations of health professional's guidelines and other publications have been reviewed. The results show an increase in aggressive and desinhibitional behavior, irritability, self-injuries and an increase in suicidal motivation with the use of antidepressants in children and adolescents. It can be added that no completed suicides have been recorded. Proof of antidepressant effectiveness only appears in the case of fluoxetine for moderate to severe depressions in children and adolescents and for tricyclic antidepressants in adolescents. The important methodological difficulties and the lack of studies only allow to consider the results as exploratory and it is hard to obtain definitive clinical results, however, they are useful to guide future investigation.
引用
收藏
页码:342 / 350
页数:9
相关论文
共 50 条
  • [1] Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)
    Hjalmarsson, L
    Corcos, M
    Jeammet, P
    [J]. ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2005, 31 (03): : 309 - 316
  • [3] Treatment of major depressive disorder in children and adolescents - Most selective serotonin reuptake inhibitors are no longer recommended
    Ramchandani, P
    [J]. BRITISH MEDICAL JOURNAL, 2004, 328 (7430): : 3 - 4
  • [4] The Use of Selective Serotonin Reuptake Inhibitors in Children and Adolescents with Major Depression
    Scahill, Lawrence
    Hamrin, Vanya
    Pachler, Mary
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHIATRIC NURSING, 2005, 18 (02) : 86 - 89
  • [5] Use of selective serotonin reuptake inhibitors in children and adolescents
    Wong, ICK
    Besag, FMC
    Santosh, PJ
    Murray, ML
    [J]. DRUG SAFETY, 2004, 27 (13) : 991 - 1000
  • [6] Use of Selective Serotonin Reuptake Inhibitors in Children and Adolescents
    Ian C.K. Wong
    Frank M.C. Besag
    Paramala J. Santosh
    Macey L. Murray
    [J]. Drug Safety, 2004, 27 : 991 - 1000
  • [7] Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy
    Strawn, Jeffrey R.
    Mills, Jeffrey A.
    Croarkin, Paul E.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2019, 29 (04) : 250 - 255
  • [8] Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder
    Bakish, D
    Cavazzoni, P
    Chudzik, J
    Ravindran, A
    Hrdina, PD
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 41 (02) : 184 - 190
  • [9] Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents
    Hetrick, S.
    Merry, S.
    McKenzie, J.
    Sindahl, P.
    Proctor, M.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
  • [10] The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder
    Clevenger, Steven S.
    Malhotra, Devvrat
    Dang, Jonathan
    Vanle, Brigitte
    IsHak, Waguih William
    [J]. THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2018, 8 (01) : 49 - 58